| Identification | Back Directory | [Name]
Razuprotafib | [CAS]
1008510-37-9 | [Synonyms]
Razuprotafib
acute,Phosphatase,Tie-2,AKB 9778,inhibit,Inhibitor,nephropathy,kidney,Razuprotafib,injury,diabetic,AKB9778
(4-((S)-2-((S)-2-((methoxycarbonyl)amino)-3-phenylpropanamido)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenyl)sulfamic acid
Carbamic acid, N-[(1S)-2-oxo-1-(phenylmethyl)-2-[[(1S)-2-[4-(sulfoamino)phenyl]-1-[2-(2-thienyl)-4-thiazolyl]ethyl]amino]ethyl]-, C-methyl ester | [Molecular Formula]
C26H26N4O6S3 | [MDL Number]
MFCD32861535 | [MOL File]
1008510-37-9.mol | [Molecular Weight]
586.7 |
| Chemical Properties | Back Directory | [density ]
1.450±0.06 g/cm3(Predicted) | [solubility ]
DMSO:100.0(Max Conc. mg/mL);170.44(Max Conc. mM) | [form ]
Solid | [pka]
-9.40±0.27(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Razuprotafib is a known VE-?PTP inhibitor that can effectively interact with the active site of VE-?PTP to inhibit the activity of VE-?PTP. | [in vivo]
Razuprotafib (20 mg/kg; s.c.) promotes phosphorylation of TIE2 in retinal endothelial cells in vivo[1].
Razuprotafib (10-20 mg/kg; s.c.; twice daily for 7 days) suppresses subretinal neovascularization (NV)[1]. |
|
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0150-83588313-811 18800520310 |
| Website: |
www.jiehuapharma.com/ |
| Company Name: |
guoyungurui
|
| Tel: |
18162595016; 18162595016 |
| Website: |
http://m.approvedhomemanagement.com/supplier/25521782/ |
|